Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

  • biotechnology industry,biotech company,clinical trials,Pfizer,Pipeline
  • fiercebiotech

Pfizer ($PFE) has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.

With the agency's designation, Pfizer is guaranteed access to top FDA officials as it develops inotuzumab ozogamicin as a treatment for acute lymphoblastic leukemia, a rare and deadly form of blood cancer. The breakthrough designation is tied to Phase III results disclosed earlier this year in which Pfizer's therapy met its goal of beating out standard care in spurring remissions for ALL patients.

Inotuzumab ozogamic is a so-called antibody-drug conjugate, hitching a cytotoxic compound to an antibody targeting the antigen CD22 and thus shuttling a cancer-killing substance straight to its malignant target. The FDA's breakthrough tag is designed to speed up the development of a treatments for unmet needs, and ALL, which affects about 6,000 Americans a year, carries a 5-year survival rate of less than 10%, Pfizer said.

The treatment's recent success is a welcome reversal for Pfizer and its oncology pipeline. The company had long heralded inotuzumab ozogamicin as a cornerstone of its ambitions in cancer therapy, but the case came apart in 2013 when the drug failed in a Phase III trial against non-Hodgkin's lymphoma, dimming analysts' expectations for its future in other diseases.

Now Pfizer is pressing forward with inotuzumab ozogamicin's Phase III ALL program. April's top-line success in remission rate was one of two primary endpoints. The second goal, overall survival, can't be measured until more patients in the study die. Pfizer plans to submit the results to regulators for approval once the study concludes.

This link:

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

2015/10/20 - Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer strikes another immunotherapy deal to widen its oncology pipeline

2014/12/10 - Pfizer has agreed to pay iTeos Therapeutics €24 million ($30 million) up front for the exclusive rights to some preclinical candidates, also making an undisclosed equity investment in the company and promising untold milestone payments down the line.

Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)

2014/07/25 - Puma Biotechnology, Inc. a development stage biopharmaceutical company, announced top line results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer (ExteNET Trial).

Pfizer Completes Acquisition Of InnoPharma

2014/09/26 - Pfizer Inc. (PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.

AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients

2014/08/13 - AstraZeneca today announced positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), as a combination therapy for the treatment of patients with symptomatic gout.

Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U.S. Academic Research Institutions Allied-Bristol Life Sciences LLC

2014/08/05 - Allied Minds and Bristol-Myers Squibb Company today announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.